- Acetylcholine is a major neurotransmitter in the brain1
- In patients with AD, cholinergic neurons are progressively lost, reducing levels of acetylcholine1
- ChEIs target cholinesterase enzymes (AChE and BuChE) and inhibit the breakdown of acetylcholine.1-3This increases the availability of acetylcholine at the cholinergic synapses.1,2
- Currently available FDA-approved ChEIs for the treatment of mild, moderate and severe AD are donepezil, rivastigmine, and galantamine1
Acess our Slide Deck on Treatment principles of Alzheimer’s disease (AD) and learn more about treatment with cholinesterase inhibitors.
Related content
Stroke, migraine, Alzheimer’s Disease and other dementias were among the top ten conditions that accounted for the greatest nervous system DALYs in 2021
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease and the leading cause of dementia worldwide, regardless of socioeconomic status.
Dementia is an umbrella term used to describe a state where an individual has lost the ability to carry out daily life activities independently because of cognitive impairment that is not due to an underlying psychiatric condition. Alzheimer’s disease (AD) refers to the abnormal presence of Aβ and tau proteins, which define AD among many other neurodegenerative diseases. Dementia -including dementia due to AD- is likely to be underestimated because of underdiagnosis and misdiagnosis.